XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaboration Agreements, License Agreement and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations Deferred Revenue (Detail) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Deferred Revenue $ 58,909 $ 2,147
AstraZeneca Agreements [Member]    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Deferred Revenue 171,516 $ 137,338
AstraZeneca Agreements [Member] | U.S./RoW and China [Member]    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Cumulative Revenue 980,531  
Deferred Revenue 171,516  
Total Consideration 1,152,047  
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | License Revenue [Member]    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Cumulative Revenue 341,844  
Deferred Revenue 0  
Total Consideration 341,844  
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | Co-development, information sharing & committee services [Member]    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Cumulative Revenue 603,119  
Deferred Revenue 0  
Total Consideration 603,119  
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | China performance obligation [Member]    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Cumulative Revenue 35,568  
Deferred Revenue 171,516  
Total Consideration $ 207,084